Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

IsraelRecruitingPHASE3

Conditions

IC-MPGN

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

    Contact: Study coordinator (Ahad Qureshi) · ahadqureshi@mednet.ucla.edu
    Contact: Principal Investigator (Lama Abdelnour)
  • Univ Cali Irvine ALS Neuromuscular, Orange, California, United States

    Contact: Study coordinator (Nancy Ortega) · nghernan@hs.uci.edu
    Contact: Principal Investigator (Ramy Hanna)
  • UCSF, San Francisco, California, United States

    Contact: Study coordinator (Juan Espinoza) · juan.espinoza@ucsf.edu · +1 415 476 5892
    Contact: Principal Investigator (Raymond Hsu)
  • Olive View UCLA Medical Center, Sylmar, California, United States

    Contact: Study coordinator (Rosario Machicado) · RMachicado@dhs.lacounty.gov
    Contact: Principal Investigator (Phuong-Chi Pham)
  • Childrens Hospital Colorado, Aurora, Colorado, United States

    Contact: Study coordinator (Kati Dugan) · Kati.Dugan@childrenscolorado.org · +1 720 777 1234
    Contact: Principal Investigator (Bradley Dixon)
  • Nicklaus Childrens Hospital, Miami, Florida, United States

    Contact: Study coordinator (Moya Chang) · Moya.chang@nicklaushealth.org · +1 786 624 4908
    Contact: Principal Investigator (Ana Paredes.)
  • Emory University School of Medicine-Winship Cancer Institute, Atlanta, Georgia, United States

    Contact: Study coordinator (Heather Jung) · heather.jung@emory.edu
    Contact: Principal Investigator (Laurence Larry Greenbaum)
  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Andrew Cao) · acao6@mgh.harvard.edu
    Contact: Principal Investigator (Meghan Sise)
  • Boston Univ School of Medicine, Boston, Massachusetts, United States

    Contact: Study coordinator (Kemberlie Adolphe) · kemberlie.adolphe@bmc.org
    Contact: Principal Investigator (Jean Francis)
  • University of Minnesota, Minneapolis, Minnesota, United States

    Contact: Study coordinator (Karen Omlung) · seve0024@umn.edu · +1 612 262 2750
    Contact: Principal Investigator (Nattawat Klomjit)
  • Washington University in St Louis, St Louis, Missouri, United States

    Contact: Study coordinator (Michelle Bloom) · mbloom@wustl.edu · +1 314 362 5298
    Contact: Principal Investigator (Tingting Li)
  • University of New Mexico, Albuquerque, New Mexico, United States

    Contact: Study coordinator (Susan L Tigert) · STigert@salud.unm.edu · +1 505 272 9992
    Contact: Principal Investigator (Namita Singh)
  • Col Uni Med Center New York Presby, New York, New York, United States

    Contact: Study coordinator (Anup Pradhan) · arp2209@cumc.columbia.edu · +1 212 304 5684
    Contact: Principal Investigator (Andrew S Bomback)
  • University Of Cincinnati, Cincinnati, Ohio, United States

    Contact: Study coordinator (Leksi Travitz) · Leksi.travitz@uc.edu
    Contact: Principal Investigator (Manish Anand)
  • OHSU Dept of Nephrology, Portland, Oregon, United States

    Contact: Study coordinator (Madison Stanaway) · stanaway@ohsu.edu · +1 503 494 4233
    Contact: Principal Investigator (Rupali Avasare)
  • Univ of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Cammy Truong) · cammy.truong@pennmedicine.upenn.edu
    Contact: Principal Investigator (Gaia Coppock)
  • MUSC Health Lancaster Med Ctr, Lancaster, South Carolina, United States

    Contact: Study coordinator (Darann Wiegand) · wiegandd@musc.edu
    Contact: Principal Investigator (Prince Anand)
  • UT Southwestern Medical Center, Dallas, Texas, United States

    Contact: Study coordinator (Melaku Lemma) · melaku.lemma@childrens.com
    Contact: Principal Investigator (Jyothsna Gattineni)
  • Prolato Clinical Research Center, Houston, Texas, United States

    Contact: Study coordinator (Romeo Parada) · rparada@prolato.org · +1 832 338 9118
    Contact: Principal Investigator (Sreedhar Mandayam.)
  • Baylor Scott and White Research, Temple, Texas, United States

    Contact: Study coordinator (Stephanie McMeen) · stephanie.mcmeen@bswhealth.org · +1 254 935 5838
    Contact: Principal Investigator (Mohanram Narayanan)
  • University of Utah, Salt Lake City, Utah, United States

    Contact: Study coordinator (Gabriella Gourdin) · gabriella.gourdin@hsc.utah.edu · +1 415 515 8212
    Contact: Principal Investigator (Raoul Nelson)
  • University of Wisconsin, Madison, Wisconsin, United States

    Contact: Study coordinator (Alana Quackenbush) · akquackenbus@wisc.edu · +1 608 265 6020
    Contact: Principal Investigator (Sharon Bartosh)
  • Novartis Investigative Site, CABA, Buenos Aires, Argentina

  • Novartis Investigative Site, CABA, Buenos Aires, Argentina

  • Novartis Investigative Site, Córdoba, Córdoba Province, Argentina

  • Novartis Investigative Site, Buenos Aires, Argentina

  • Novartis Investigative Site, CABA, Argentina

  • Novartis Investigative Site, Santa Fe, Argentina

  • Novartis Investigative Site, Fortaleza, Ceará, Brazil

  • Novartis Investigative Site, Brasília, Federal District, Brazil

  • Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil

  • Novartis Investigative Site, Recife, Pernambuco, Brazil

  • Novartis Investigative Site, Niterói, Rio de Janeiro, Brazil

  • Novartis Investigative Site, Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site, Natal, Rio Grande do Norte, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Botucatu, São Paulo, Brazil

  • Novartis Investigative Site, Santo André, São Paulo, Brazil

  • Novartis Investigative Site, Sao Jose Rio Preto, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Salvador, Brazil

  • Novartis Investigative Site, Etobicoke, Ontario, Canada

  • Novartis Investigative Site, Toronto, Ontario, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Aarhus N, Denmark

  • Novartis Investigative Site, Copenhagen, Denmark

  • Novartis Investigative Site, Marseille, France

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Rennes, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Munich, Bavaria, Germany

  • Novartis Investigative Site, Würzburg, Bavaria, Germany

  • Novartis Investigative Site, Dresden, Saxony, Germany

  • Novartis Investigative Site, Jena, Thuringia, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Hamburg, Germany

  • Novartis Investigative Site, Hanover, Germany

  • Novartis Investigative Site, Mainz, Germany

  • Novartis Investigative Site, Ulm, Germany

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Chaïdári, Greece

  • Novartis Investigative Site, Heraklion Crete., Greece

  • Novartis Investigative Site, Ioannina, Greece

  • Novartis Investigative Site, Pátrai, Greece

  • Novartis Investigative Site, Thessaloniki, Greece

  • Novartis Investigative Site, Thessaloniki, Greece

  • Novartis Investigative Site, Bangalore, Karnataka, India

  • Novartis Investigative Site, Nagpur, Maharashtra, India

  • Novartis Investigative Site, Pune, Maharashtra, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, Hyderabad, Telangana, India

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Petah Tikva, Israel

  • Novartis Investigative Site, Bari, BA, Italy

  • Novartis Investigative Site, Ranica, BG, Italy

  • Novartis Investigative Site, Brescia, BS, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Torino, TO, Italy

  • Novartis Investigative Site, Naples, Italy

  • Novartis Investigative Site, Toyoake, Aichi-ken, Japan

  • Novartis Investigative Site, Fuchū, Tokyo, Japan

  • Novartis Investigative Site, Hachiōji, Tokyo, Japan

  • Novartis Investigative Site, Okayama, Japan

  • Novartis Investigative Site, Osaka, Japan

  • Novartis Investigative Site, Groningen, Netherlands

  • Novartis Investigative Site, Poznan, Greater Poland Voivodeship, Poland

  • Novartis Investigative Site, Bialystok, Poland

  • Novartis Investigative Site, Krakow, Poland

  • Novartis Investigative Site, Olsztyn, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Wroclaw, Poland

  • Novartis Investigative Site, Martin, Slovakia, Slovakia

  • Novartis Investigative Site, Banská Bystrica, Slovakia

  • Novartis Investigative Site, Košice, Slovakia

  • Novartis Investigative Site, Seoul, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Pamplona, Navarre, Spain

  • Novartis Investigative Site, Almería, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Salamanca, Spain

  • Novartis Investigative Site, Bern, Switzerland

  • Novartis Investigative Site, Lausanne, Switzerland

  • Novartis Investigative Site, Zurich, Switzerland

  • Novartis Investigative Site, Kaohsiung City, Taiwan

  • Novartis Investigative Site, Istanbul, Fatih, Turkey (Türkiye)

  • Novartis Investigative Site, Izmir, Karsiyaka, Turkey (Türkiye)

  • Novartis Investigative Site, Köseköy, Kocaeli, Turkey (Türkiye)

  • Novartis Investigative Site, Kayseri, Melikgazi, Turkey (Türkiye)

  • Novartis Investigative Site, Ankara, Yenimahalle, Turkey (Türkiye)

  • Novartis Investigative Site, Mersin, Yenisehir, Turkey (Türkiye)

  • Novartis Investigative Site, Belfast, United Kingdom

  • Novartis Investigative Site, Cardiff, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, Manchester, United Kingdom

  • Novartis Investigative Site, Salford, United Kingdom

  • Novartis Investigative Site, Ho Chi Minh City, Vietnam

Study leads
  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals